Biocryst.com

Site Inspections

Overview & More informations

BioCryst Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes novel small molecule drugs to treat rare diseases in which significant unmet medical needs exist. The company's lead product candidate is BCX7353, a novel oral treatment for hereditary angioedema (HAE). BCX7353 is currently in Phase 3 clinical development and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA).

BioCryst was founded in 1996 and is headquartered in Durham, NC. The company has a market cap of $1.2 billion and employs approximately 300 people. BioCryst's stock is traded on the Nasdaq under the symbol "BCRX".

The company's technology platform is based on its proprietary Structure-Based Drug Design (SBDD) approach. SBDD uses computer modeling to identify and design small molecule drugs that target specific protein structures. BioCryst's SBDD platform has been used to develop a number of novel drug candidates, including BCX7353.

BioCryst's pipeline includes several other clinical-stage drug candidates, including:

* BCX9930, a novel oral treatment for paroxysmal nocturnal hemoglobinuria (PNH)
* BCX9250, a novel oral treatment for gout
* BCX7090, a novel oral treatment for diabetic macular edema (DME)

BioCryst is a leading biotechnology company with a promising pipeline of novel drug candidates. The company's SBDD platform is a valuable asset, and BioCryst is well-positioned to develop and commercialize new treatments for rare diseases.

Domains Expiration Date Updated